Team

Matthew Caldemeyer, M.B.A., is the Chief Business Officer of Recludix Pharma. He led the execution of the company’s strategic collaboration with Sanofi to advance a novel oral STAT6 inhibitor.  Prior to Recludix, he was the Vice President of Business Development at Everest Medicines where he led business development transactions and managed a key alliance with Gilead. He previously served as Head of Business Development at Ambrx and as Director of Corporate Strategy and Business Development at Array BioPharma. From 2011 to 2015, Mr. Caldemeyer held progressive roles in strategy and corporate development at Amgen, based both in the United States and Switzerland. From 2004 to 2011, Mr. Caldemeyer was at Eli Lilly and Company where he held positions in business development, finance and manufacturing. Mr. Caldemeyer obtained a B.S. from Michigan State University and an M.B.A. in finance from the Kelley School of Business at Indiana University.